Condition: Advanced Malignant Solid Neoplasm · Metastatic Malignant Solid Neoplasm · Unresectable Malignant Solid Neoplasm · Sponsor: National Cancer Institute (NCI)
This phase II trial tests whether ZEN003694 (ZEN-3694) in combination with talazoparib works to shrink tumors in patients with solid tumors that are unlikely to be cured or controlled with treatment and that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Another aim of this study is to find out if, and how, patients' genes influence their response to this specific drug combination. For this part of the study, investigators will run tests using samples of patients' tumor tissue and blood that will be collected during the study. ZEN-3694 is an inhibitor of a family of proteins called the bromodomain and extra-terminal (BET). It may prevent the growth of tumor cells that overproduce BET protein. Talazoparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Genes are pieces of the DNA code that individuals inherit from their parents. Some genes work to protect against cancer by correcting damage that can occur in the DNA when cells divide. BRCA1 and BRCA2 are two examples of these types of genes, and they are called tumor-suppressor genes. For example, if a person has a mutation in a BRCA1/2 gene they have a greatly increased risk of developing breast and ovarian cancer because their cells may no longer be able to c…
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| City of Hope Comprehensive Cancer Center | Duarte, California, United States | Recruiting |
| City of Hope at Irvine Lennar | Irvine, California, United States | Recruiting |
| UC San Diego Moores Cancer Center | La Jolla, California, United States | Recruiting |
| Keck Medicine of USC Koreatown | Los Angeles, California, United States | Active Not Recruiting |
| Los Angeles General Medical Center | Los Angeles, California, United States | Active Not Recruiting |
| USC / Norris Comprehensive Cancer Center | Los Angeles, California, United States | Active Not Recruiting |
| USC Norris Oncology/Hematology-Newport Beach | Newport Beach, California, United States | Active Not Recruiting |
| University of California Davis Comprehensive Cancer Center | Sacramento, California, United States | Active Not Recruiting |
| UC San Diego Medical Center - Hillcrest | San Diego, California, United States | Recruiting |
| UCHealth University of Colorado Hospital | Aurora, Colorado, United States | Active Not Recruiting |
| Yale University | New Haven, Connecticut, United States | Active Not Recruiting |
| Smilow Cancer Hospital Care Center-Trumbull | Trumbull, Connecticut, United States | Active Not Recruiting |
+ 24 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05327010